Soumaya L, Nesrine M, Houda EB, Mehdi A, Sarra L, Hamouda B. Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice. Cancer Chemother Pharmacol. Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice
INTRODUCTION: We aim to evaluate prevalence and characteristics of CTS in routine daily practice over a 5-year period, with a review of the literature.
METHODS: Patients treated with endocrine therapy (441) were retrospectively analyzed looking for CTS cases in aromatase inhibitors (219, 49.6%) and in tamoxifen (222, 50.3%) patients. We described patient's characteristics and CTS management. We also reviewed the literature reporting CTS in aromatase inhibitors clinical trials.
RESULTS: Six cases of CTS were diagnosed, all in patients on aromatase inhibitors given in the adjuvant setting. Prevalence was 2.7%. Median age was 54 years. CTS occurred under anastrozole in four cases and letrozole in two cases. One patient had severe intensity presentation. Median time to symptoms onset was 14 months, and resolution was obtained within 4 months after a nonsurgical treatment.
CONCLUSION: Aromatase inhibitor-induced CTS is rare. It should be recognized and treated in order to avoid endocrine therapy discontinuation.
INTRODUCTION: We aim to evaluate prevalence and characteristics of CTS in routine daily practice over a 5-year period, with a review of the literature.
METHODS: Patients treated with endocrine therapy (441) were retrospectively analyzed looking for CTS cases in aromatase inhibitors (219, 49.6%) and in tamoxifen (222, 50.3%) patients. We described patient's characteristics and CTS management. We also reviewed the literature reporting CTS in aromatase inhibitors clinical trials.
RESULTS: Six cases of CTS were diagnosed, all in patients on aromatase inhibitors given in the adjuvant setting. Prevalence was 2.7%. Median age was 54 years. CTS occurred under anastrozole in four cases and letrozole in two cases. One patient had severe intensity presentation. Median time to symptoms onset was 14 months, and resolution was obtained within 4 months after a nonsurgical treatment.
CONCLUSION: Aromatase inhibitor-induced CTS is rare. It should be recognized and treated in order to avoid endocrine therapy discontinuation.
